drugset / Trial / NCT04755088
Surufatinib Renal Impairment Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label, multicenter, single-dose, single-period, sequential study to assess the effect of moderate renal impairment on the pharmacokinetics of surufatinib.
Timeline
- Start
- 2021-02-12
- Primary completion
- 2021-08-21
- Completion
- 2021-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |